Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Experimental and Therapeutic Medicine
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-0981 Online ISSN: 1792-1015
Journal Cover
June-2014 Volume 7 Issue 6

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
June-2014 Volume 7 Issue 6

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Effects of different mitomycin C concentrations on laser-assisted subepithelial keratectomy

  • Authors:
    • Jianjiang Shi
    • Yaoxin Yuan
    • Suxia Zhao
    • Jianlong Xu
    • Meng Guo
  • View Affiliations / Copyright

    Affiliations: Department of Ophthalmology, Second Affiliated Hospital of Xingtai Medical College, Xingtai, Hebei 054000, P.R. China
  • Pages: 1591-1594
    |
    Published online on: March 28, 2014
       https://doi.org/10.3892/etm.2014.1642
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

The aim of the present study was to determine the effect of different concentrations of mitomycin C (MMC) administered intraoperatively during laser‑assisted subepithelial keratectomy (LASEK) surgery. A total of 261 patients (496 eyes) were randomly divided into two groups: 0.04% MMC treatment group consisting of 133 patients (245 eyes) and the 0.02% MMC treatment group consisting of 128 patients (251 eyes). The MMC solutions were dropped intraoperatively onto the ablation region and the duration was dependent on the preoperative refractive power of the patient's cornea: ≤-3.00 diopters (D), 30 sec; between ‑3.25 D and ‑6.00 D, 60 sec; between ‑6.25 D and ‑9.00 D, 90 sec and ≥-9.25 D, 110 sec. Postoperative observations included haze formation, visual acuity, changes in refractive power, corneal endothelial cell density and incidence of complications. The one year postoperative incidence of haze differed significantly between the groups (P<0.05). The one week and one year comparisons of postoperative visual acuity also differed significantly between the groups (P<0.05). Postoperative changes in corneal refractive power at one, six and 12 months following surgery significantly differed between the groups (P<0.05). No statistically significant difference was identified between the density of corneal endothelial cells prior to surgery and the density at one, six and 12 months following surgery (P>0.05). Thus, the intraoperative application of 0.04% MMC solution effectively inhibited haze formation and markedly improved the efficacy of LASEK surgery, when compared with that of 0.02% MMC.

Introduction

Laser-assisted subepithelial keratectomy (LASEK) surgery was introduced in 1999 to eliminate the flap-related complications of laser-assisted in situ keratomileusis (LASIK) surgery. The LASEK surgical procedure reduces significant postoperative pain, corneal haze and prevents the flap and interface-related problems associated with LASIK surgery (1). Furthermore, LASEK surgery increases visual acuity and decreases aberrations and other defects (2). Patients undergoing LASEK surgery reportedly have reduced risks of postoperative ectasia, indicating that this surface treatment may be safer, particularly when the patients are highly myopic or have thin corneas. However, other complications remain, including haze and regression, which limit the development of LASEK surgery. The present study investigated the postoperative effects of administering different concentrations of mitomycin C (MMC) during LASEK surgery.

Patients and methods

Patients

A total of 261 patients were enrolled in the present study. The subjects were aged ≤18 years and were scheduled to undergo LASEK surgery between June 2007 and June 2008. This study was a prospective, randomized, single-center study and all surgical procedures were performed by one surgeon. The 0.04% MMC group comprised 133 patients (245 eyes), including 58 males (112 eyes) and 75 females (113 eyes), aged between 18 and 46 years (mean age, 23.7 years). A total of 28 patients (51 eyes) exhibited low myopia [≤−3.00 diopters (D)], 39 patients (71 eyes) exhibited medium myopia (between 3.25 D and −6.00 D), 31 patients (55 eyes) exhibited high myopia (between 6.25 D and 9.00 D) and 35 patients (68 eyes) exhibited extremely high myopia (≥−9.25 D). The 0.02% MMC group comprised 128 patients (251 eyes), including 61 males (119 eyes) and 67 females (132 eyes), aged between 18 and 44 years (mean age, 22.1 years). A total of 31 patients (59 eyes) exhibited low myopia, 38 patients (76 eyes) exhibited medium myopia, 33 patients (64 eyes) exhibited high myopia and 26 patients (52 eyes) exhibited extremely high myopia. The study was conducted in accordance with the Declaration of Helsinki and approval was obtained from the Ethics Committee of Xingtai Medical College (Xingtai, China). Written informed consent was obtained from all participants.

Preoperative examination

All patients were subjected to a slit lamp test (SLM-2, Seetool Instrument Co., Ltd., Chongqing, China), a fundoscopic examination (YZ11D Ophthalmoscope and YZ25A Indirect Ophthalmoscope, 66 Vision-Tech Co., Ltd., Suzhou, China), an electronic optometry examination (Accuref-K 9001; Central Medical Ltd., Fukuoka, Japan), a combined optometry examination (Marco CP-690), corneal topography (ATLAS® 995; Carl Zeiss Meditec AG, Oberkochen, Germany), a corneal endothelium cell count, intraocular pressure measurement (AT555, Seetool Instrument Co., Ltd., Chongqing, China) and the corneal thickness was measured via ultrasound (Tomey SP-3000; Tomey Corp., Nagoya, Japan).

Surgical procedure

All patients were administered topical anesthesia (C17H28N2O3·HCl eye drops; twice or three times into the conjunctival sac before surgery; Sam Chun Dang Pharm Co., Ltd., Tokyo, Japan) and received LASEK surgery, according to their optimal preoperative corneal refractive power, via a MEL 80™ Excimer Laser System (Carl Zeiss Meditec AG). The central 8-mm surface region of the cornea was infiltrated with 20% alcohol for 15–25 sec under a microscope and the corneal flap was opened. Following incision using an excimer laser, the surgical area was immediately instilled with 0.02 or 0.04% MMC for a duration that was dependent on the patient’s optimal preoperative corneal refractive power: ≤−3.00 diopters (D), 30 sec; between −3.25 and −6.00 D, 60 sec; between −6.25 and −9.00 D, 90 sec; and ≥−9.25 D, 110 sec. The surgical area was rinsed using physiological saline solution. Following resetting of the corneal flap, a soft corneal contact lens was applied.

Postoperative medication and follow-up

Tobramycin and dexamethasone eye drops (Guoguang Pharmaceutical Company, Hangzhou, China) were applied four times within 60 min immediately after the surgery and then a further four times in the remaining time of the same day (a total of eight times that day). Then they were administered 7 times the next day, 6 the third day, 5 the fourth day and then 4 times for the next 3 days.

One week following surgery, 0.1% fluorometholone eye drops (Osaka, Japan) were applied four times per day for three weeks, three times per day for three weeks, twice per day for three weeks and once per day for three weeks.

Diclofenac sodium eye drops (0.1%; Hubei Qianjiang Pharmaceutical Co., Ltd., Qianjiang, China) were also administered after the surgery for a week, 4 times per day. Sodium hyaluronate eye drops (Ursapharm Arzneimittel GmbH, Saarbrücken, Germany) were also administered after the surgery, four times per day for whole three months.

Patients were examined once every 2–3 weeks and were followed-up routinely for 1–2 years postoperatively.

Statistical analysis

The incidence of haze visual acuity was analyzed using a χ2 test. Variations in corneal refractive power and corneal endothelial cell counts were analyzed using a t-test. P<0.05 was considered to indicate a statistically significant difference.

Results

Treatment

The incidence of haze with 0.04% MMC was 1.22%, while for 0.02% MMC, the incidence was 13.15%. The one year postoperative incidence of haze differed significantly between the groups (P<0.05; Table I). As shown in Table II, the one week and one year comparisons of postoperative visual acuity differed significantly between the groups (P<0.05). The postoperative changes in corneal refractive power at one, six and 12 months following surgery significantly differed between the groups (Table III). No significant difference was identified in the density of corneal endothelial cells prior to surgery or at one, six and 12 months following surgery (P>0.05;Table IV).

Table I

Incidence of haze one year following surgery (scoring according to the Fantes grading scale).

Table I

Incidence of haze one year following surgery (scoring according to the Fantes grading scale).

Incidence of haze, n

GroupTotal eyes, nGrade IGrade IIGrade IIIRate, %
0.04% MMC2450301.22
0.02% MMC2511810513.15

[i] MMC, mitomycin C.

Table II

Comparison of postoperative visual acuity with different MMC solutions.

Table II

Comparison of postoperative visual acuity with different MMC solutions.

Optimal visual acuity, n (%)

GroupTotal eyes, n1 week3 weeks1 year
0.04% MMC245157 (64.08)245 (100)243 (99.18)
0.02% MMC251180 (72.11)251 (100)246 (98.01)

[i] MMC, mitomycin C.

Table III

Changes in corneal refractive power measured in diopters (D).

Table III

Changes in corneal refractive power measured in diopters (D).

Eyes exhibiting changes in corneal refractive power

Group1 month6 months1 year
0.04% MMC−0.52±0.09−0.29±0.15−0.35±0.16
0.02% MMC−0.67±0.11−0.58±0.21−0.54±0.18

[i] Values are expressed as mean ± SD. MMC, mitomycin C.

Table IV

Density of corneal endothelial cells.

Table IV

Density of corneal endothelial cells.

Density of corneal endothelial cells, cells/mm2

GroupPreoperativePostoperative 1 monthPostoperative 6 monthsPostoperative 12 months
0.04% MMC2,994.01±321.892,974.89±339.873,001.02±306.923,011.18±321.31
0.02% MMC3,005.92±382.542,996.69±374.192,988.37±367.333,000.05±299.84

[i] Values are expressed as mean ± SD. MMC, mitomycin C.

Complications

All patients exhibiting marginal epidermal edema were observed on day 1 and the edema was resolved by day 5. Filamentary keratitis occurred in two patients in the 0.04% MMC group (one bilateral and one unilateral) and in two patients in the 0.02% MMC group (both unilateral).

Discussion

MMC, an antineoplastic antibiotic produced by Streptomyces caespitosus, is a bi- or tri-functional alkylating agent that causes DNA cross-linking and inhibits DNA synthesis. MMC inhibits the growth of numerous types of cell and although MMC is a systemic chemotherapeutic agent, it is commonly applied locally at ophthalmic surgical sites to prevent recurrence, such as in glaucoma, pterygium excision and conjunctival resection (3,4). The activity and biotoxicity of MMC is closely associated with the dosage and usage (5,6). Previous studies identified that the biotoxicity of MMC increased with the dosage and contact time and the effect persisted following treatment (7,8). Biotoxicity of MMC is severe; however, 0.04 mg/ml MMC has been identified as safe and has been used on eye tissues during glaucoma filtration surgery. In the present study, the MMC solution was intraoperatively administered during LASEK surgery. The solution was only in contact with the surface of the cornea and did not affect surrounding cells, thereby minimizing MMC biotoxicity.

Camellin (9) and Virasch et al (10) introduced photorefractive keratectomy with an epithelial flap in 1999; this method was subsequently termed LASEK. LASEK was a revision of previous techniques and aimed to improve the postoperative time course and healing process, prevent flap trauma and offer an alternative treatment method for patients with thin corneas. Despite the similarities between LASEK and earlier technologies, the debate surrounding its legitimacy may be irrelevant if results indicate considerable superiority over previous techniques.

LASEK is an important development in refraction correction surgery; however, numerous complications remain, including haze, refractive regression and visual acuity decrease, which restrict further development of this method. Although a number of corneal epithelial cells withstand LASEK surgery and the survival of corneal epithelium cells moderately inhibits haze formation (11,12), haze remains a common complication of various techniques. Previous studies have shown that haze increases the proliferation and activity of corneal cells and results in the irregular arrangement of fibers during novel extracellular matrix synthesis (13). Although LASEK surgery retains the corneal epithelium, ethanol soaks into the matrix system valve plane located between the membrane and the dense plate, triggering postoperative healing of the corneal wound (which normally results in haze formation) (14). Excimer laser surgery is considered to be a stimulus for corneal tissue trauma, therefore, the occurrence of haze is directly associated with wound healing of the corneal tissue (15). The primary method of preventing haze formation is the use of glucocorticosteroids in the ocular region; however, glucocorticosteroid use may result in ocular hypertension, corticosteroid-induced glaucoma and cataracts. Antihyperplasia drugs have been administered in the ocular region to inhibit haze formation (16–19), however, administering MMC in the ocular region inhibits hyperplasia of the corneal epithelium, fibroblasts and collagen fibers, as well as inhibiting haze formation. Furthermore, MMC treatment induces apoptosis of keratocytes and myofibroblasts; however, the mechanism of action underlying the inhibition of haze involves blocking the replication of keratocytes or other myofibroblast progenitor cells (20).

In the present study, two concentrations of MMC were administered during surgery to inhibit haze formation. Corneal haze formation, visual acuity, changes in refractive power, corneal endothelial cell density and corneal healing were observed. The 0.04% MMC group comprised 133 patients, (245 eyes), 58 males (112 eyes) and 75 females (113 eyes) aged between 18 and 46 years (mean age, 23.7 years). A total of 28 patients (51 eyes) exhibited low myopia, 39 patients (71 eyes) exhibited medium myopia, 31 patients (55 eyes) exhibited high myopia and 35 patients (68 eyes) exhibited extremely high myopia. The 0.02% MMC group comprised 128 patients (251 eyes), including 61 males (119 eyes) and 67 females (132 eyes) aged between 18 and 44 years (mean age, 22.1 years). A total of 31 patients (59 eyes) exhibited low myopia, 38 patients (76 eyes) exhibited medium myopia, 331 patients (64 eyes) exhibited high myopia and 26 patients (52 eyes) exhibited extremely high myopia.

In conclusion, the present study indicates that intraoperative application of 0.04% MMC solution effectively inhibits haze formation and markedly improves the outcome of LASEK surgery as compared with the administration of 0.02% MMC.

Acknowledgements

This study was supported by the Science Research Foundation of the Education Department, Hebei, China (grant no. 2008482).

References

1 

Lee JB, Seong GJ, Lee JH, et al: Comparison of laser epithelial keratomileusis and photorefractive keratectomy for low to moderate myopia. J Cataract Refract Surg. 27:565–570. 2001. View Article : Google Scholar : PubMed/NCBI

2 

Scerrati E: Laser in situ keratomileusis vs. laser epithelial keratomileusis (LASIK vs LASEK). J Refract Surg. 17(Suppl 2): S219–S221. 2001.PubMed/NCBI

3 

Joos KM, Bueche MJ, Palmberg PF, Feuer WJ and Grajewski AL: One-year follow-up results of combined mitomycin C trabeculectomy and extracapsular cataract extraction. Opthalmology. 102:76–83. 1995.PubMed/NCBI

4 

Panda A, Bajaj MS, Balasubramanya R and Prakash G: Topical mitomycin C for conjunctival-corneal squamous cell carcinoma. Am J Ophthalmol. 135:122–124. 2003. View Article : Google Scholar : PubMed/NCBI

5 

Ando H, Ido T, Kawai Y, Yamamoto T and Kitazawa Y: Inhibition of corneal epithelial wound healing. A comparative study of mitomycin C and 5-fluorouracil. Ophthalmology. 99:1809–1814. 1992. View Article : Google Scholar : PubMed/NCBI

6 

Yamamoto T, Varani J, Soong HK and Lichter PR: Effects of 5-fluorouracil and mitomycin C on cultured rabbit subconjunctival fibroblasts. Ophthalmology. 97:1204–1210. 1990. View Article : Google Scholar : PubMed/NCBI

7 

Sadeghi HM, Seitz B, Hayashi S, LaBree L and McDonnell PJ: In vitro effects of mitomycin-C on human keratocytes. J Refract Surg. 14:534–540. 1998.PubMed/NCBI

8 

Khaw PT, Sherwood MB, MacKay SL, Rossi MJ and Schultz G: Five-minute treatments with fluorouracil, floxuridine, and mitomycin have long-term effects on human Tenon’s capsule fibroblasts. Arch Ophthalmol. 110:1150–1154. 1992.PubMed/NCBI

9 

Camellin M: LASEK may offer the advantages of both LASIK and PRK. Ocu Surg N Int. 10:14–15. 1999.

10 

Virasch VV, Majmudar PA, Epstein RJ, Vaidya NS and Dennis RF: Reduced application time for prophylactic mitomycin C in photorefractive keratectomy. Ophthalmology. 117:885–889. 2010. View Article : Google Scholar : PubMed/NCBI

11 

Autrata R and Rehurek J: Laser-assisted subepithelial keratectomy for myopia: two-year follow-up. J Cataract Refract Surg. 29:661–668. 2003.PubMed/NCBI

12 

Autrata R and Rehurek J: Laser-assisted subepithelial keratectomy and photorefractive keratectomy for the correction of hyperopia. Results of a 2-year follow-up. J Cataract Refract Surg. 29:2105–2114. 2003.PubMed/NCBI

13 

Lohmann CP, Gartry DS, Kerr Muir M, Timberlake GT, Fitzke FW and Marshall J: ‘Haze’ in photorefractive keratectomy: its origins and consequences. Laser Light Opthalmol. 4:15–34. 1991.

14 

Espana EM, Grueterich M, Mateo A, et al: Cleavage of corneal basement membrane components by ethanol exposure in laser-assisted subepithelial keratectomy. J Cataract Refract Surg. 29:1192–1197. 2003. View Article : Google Scholar

15 

Ahmadi AJ and Jakobiec FA: Corneal wound healing: cytokines and extracellular matrix proteins. Int Ophthalmol Clin. 42:13–22. 2002. View Article : Google Scholar : PubMed/NCBI

16 

Majmudar PA, Forstot SL, Dennis RF, et al: Topical mitomycin-C for subepithelial fibrosis after refractive corneal surgery. Ophthalmolgogy. 107:89–94. 2000. View Article : Google Scholar : PubMed/NCBI

17 

Vigo L, Scandola E and Carones F: Scraping and mitomycin C to treat haze and regression after photorefractive keratectomy for myopia. J Refract Surg. 19:449–454. 2003.PubMed/NCBI

18 

Mirza MA, Qazi MA and Pepose JS: Treatment of dense subepithelial corneal haze after laser-assisted subepithelial keratectomy. J Cataract Refract Surg. 30:709–714. 2004. View Article : Google Scholar : PubMed/NCBI

19 

Carones F, Vigo L, Scandola E and Vacchini L: Evaluation of the prophylactic use of mitomycin-C to inhibit haze formation after photorefractive keratectomy. J Cataract Refract Surg. 28:2088–2095. 2002. View Article : Google Scholar : PubMed/NCBI

20 

Netto MV, Mohan RR, Sinha S, Sharma A, Gupta PC and Wilson SE: Effect of prophylactic and therapeutic mitomycin C on corneal apoptosis, cellular proliferation, haze, and long-term keratocyte density in rabbits. J Refract Surg. 22:562–574. 2006.PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Shi J, Yuan Y, Zhao S, Xu J and Guo M: Effects of different mitomycin C concentrations on laser-assisted subepithelial keratectomy. Exp Ther Med 7: 1591-1594, 2014.
APA
Shi, J., Yuan, Y., Zhao, S., Xu, J., & Guo, M. (2014). Effects of different mitomycin C concentrations on laser-assisted subepithelial keratectomy. Experimental and Therapeutic Medicine, 7, 1591-1594. https://doi.org/10.3892/etm.2014.1642
MLA
Shi, J., Yuan, Y., Zhao, S., Xu, J., Guo, M."Effects of different mitomycin C concentrations on laser-assisted subepithelial keratectomy". Experimental and Therapeutic Medicine 7.6 (2014): 1591-1594.
Chicago
Shi, J., Yuan, Y., Zhao, S., Xu, J., Guo, M."Effects of different mitomycin C concentrations on laser-assisted subepithelial keratectomy". Experimental and Therapeutic Medicine 7, no. 6 (2014): 1591-1594. https://doi.org/10.3892/etm.2014.1642
Copy and paste a formatted citation
x
Spandidos Publications style
Shi J, Yuan Y, Zhao S, Xu J and Guo M: Effects of different mitomycin C concentrations on laser-assisted subepithelial keratectomy. Exp Ther Med 7: 1591-1594, 2014.
APA
Shi, J., Yuan, Y., Zhao, S., Xu, J., & Guo, M. (2014). Effects of different mitomycin C concentrations on laser-assisted subepithelial keratectomy. Experimental and Therapeutic Medicine, 7, 1591-1594. https://doi.org/10.3892/etm.2014.1642
MLA
Shi, J., Yuan, Y., Zhao, S., Xu, J., Guo, M."Effects of different mitomycin C concentrations on laser-assisted subepithelial keratectomy". Experimental and Therapeutic Medicine 7.6 (2014): 1591-1594.
Chicago
Shi, J., Yuan, Y., Zhao, S., Xu, J., Guo, M."Effects of different mitomycin C concentrations on laser-assisted subepithelial keratectomy". Experimental and Therapeutic Medicine 7, no. 6 (2014): 1591-1594. https://doi.org/10.3892/etm.2014.1642
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team